BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 30217320)

  • 1. Comparative effectiveness of preoperative, postoperative and perioperative treatments for resectable gastric cancer: A network meta-analysis of the literature from the past 20 years.
    Cai Z; Yin Y; Shen C; Wang J; Yin X; Chen Z; Zhou Y; Zhang B
    Surg Oncol; 2018 Sep; 27(3):563-574. PubMed ID: 30217320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis.
    Cai Z; Yin Y; Yin Y; Shen C; Wang J; Yin X; Chen Z; Zhou Y; Zhang B
    Gastric Cancer; 2018 Nov; 21(6):1031-1040. PubMed ID: 29728791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis.
    Kumagai K; Rouvelas I; Tsai JA; Mariosa D; Lind PA; Lindblad M; Ye W; Lundell L; Schuhmacher C; Mauer M; Burmeister BH; Thomas JM; Stahl M; Nilsson M
    Eur J Surg Oncol; 2015 Mar; 41(3):282-94. PubMed ID: 25491892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis.
    Chan KKW; Saluja R; Delos Santos K; Lien K; Shah K; Cramarossa G; Zhu X; Wong RKS
    Int J Cancer; 2018 Jul; 143(2):430-437. PubMed ID: 29441562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Neoadjuvant Treatments for Resectable Gastroesophageal Cancer: A Network Meta-Analysis.
    Cai Z; Yin Y; Zhao Z; Xin C; Cai Z; Yin Y; Shen C; Yin X; Wang J; Chen Z; Zhou Y; Zhang B
    Front Pharmacol; 2018; 9():872. PubMed ID: 30127746
    [No Abstract]   [Full Text] [Related]  

  • 6. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG.
    Leong T; Smithers BM; Haustermans K; Michael M; Gebski V; Miller D; Zalcberg J; Boussioutas A; Findlay M; O'Connell RL; Verghis J; Willis D; Kron T; Crain M; Murray WK; Lordick F; Swallow C; Darling G; Simes J; Wong R
    Ann Surg Oncol; 2017 Aug; 24(8):2252-2258. PubMed ID: 28337660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodal treatments for resectable gastric cancer: A systematic review and network meta-analysis.
    Cheng J; Cai M; Shuai X; Gao J; Wang G; Tao K
    Eur J Surg Oncol; 2019 Oct; 45(10):1796-1805. PubMed ID: 31204169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The optimal strategy of multimodality therapies for resectable gastric cancer: evidence from a network meta-analysis.
    Yin S; Wang P; Xu X; Tan Y; Huang J; Xu H
    J Cancer; 2019; 10(14):3094-3101. PubMed ID: 31289579
    [No Abstract]   [Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy for nonmetastatic esophago-gastric adenocarcinomas: a systematic review and meta-analysis.
    Zhang CD; Zeng YJ; Li HW; Zhao ZM; Zhang JK; Dai DQ
    Cancer Invest; 2013 Jul; 31(6):421-31. PubMed ID: 23758189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis.
    Malthaner RA; Wong RK; Rumble RB; Zuraw L;
    BMC Med; 2004 Sep; 2():35. PubMed ID: 15447788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data.
    Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Schuhmacher C; Urba S; van de Velde C; Walsh TN; Ychou M; Jensen K
    Eur J Cancer; 2013 Oct; 49(15):3149-58. PubMed ID: 23800671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).
    Leong T; Smithers BM; Michael M; Gebski V; Boussioutas A; Miller D; Simes J; Zalcberg J; Haustermans K; Lordick F; Schuhmacher C; Swallow C; Darling G; Wong R
    BMC Cancer; 2015 Jul; 15():532. PubMed ID: 26194186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes after different treatments for gastric cancer with synchronous liver metastasis: A PRISMA systematic review and network meta-analysis.
    Li M; Yang B
    Medicine (Baltimore); 2022 Jun; 101(25):e29533. PubMed ID: 35758396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative chemoradiotherapy versus postoperative chemotherapy for completely resected gastric cancer with D2 Lymphadenectomy: a meta-analysis.
    Huang YY; Yang Q; Zhou SW; Wei Y; Chen YX; Xie DR; Zhang B
    PLoS One; 2013; 8(7):e68939. PubMed ID: 23874819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma: A Network Meta-analysis.
    Pasquali S; Yim G; Vohra RS; Mocellin S; Nyanhongo D; Marriott P; Geh JI; Griffiths EA
    Ann Surg; 2017 Mar; 265(3):481-491. PubMed ID: 27429017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis.
    van den Ende T; Ter Veer E; Machiels M; Mali RMA; Abe Nijenhuis FA; de Waal L; Laarman M; Gisbertz SS; Hulshof MCCM; van Oijen MGH; van Laarhoven HWM
    Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30641964
    [No Abstract]   [Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy brings more survival benefits than postoperative chemotherapy for resectable gastric cancer: a Meta-analysis of randomized controlled trials.
    Hu Y; Hu D; Li W; Yu X
    J BUON; 2019; 24(1):201-214. PubMed ID: 30941971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic options in gastric cancer: neoadjuvant chemotherapy vs postoperative chemoradiotherapy.
    Jackson C; Mochlinski K; Cunningham D
    Oncology (Williston Park); 2007 Aug; 21(9):1084-7; discussion 1090, 1096-8, 1101. PubMed ID: 17910312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Efficacy of Preoperative, Postoperative, and Perioperative Treatments for Resectable Colorectal Liver Metastases: A Network Meta-Analysis.
    Huang C; Huang J; Luo H; Zong Z; Zhu Z
    Front Pharmacol; 2019; 10():1052. PubMed ID: 31619998
    [No Abstract]   [Full Text] [Related]  

  • 20. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
    Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K;
    Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.